OpenAI Acquires Orchestra Bio, Expanding AI Agent Play in Drug Development
Sign in✓ Signed in
OpenAI has acquired Orchestra Bio, an R&D management platform for biotech and pharmaceutical companies, signaling the AI company's deepening commitment to autonomous agents for scientific workflows. Orchestra, founded in 2022 by CEO Ashoka Rajendra (formerly at Benchling) and CTO Andy Xu, provides enterprise software that unifies scientific roadmaps, budgets, hiring plans, and experiment tracking with AI-assisted decision support for drug development teams.
Continue reading
The rest of this article is for AI News Blitz readers. Choose an option below to keep reading.
Already purchased? Sign in✓ Signed in — this article isn’t included in your current plan.
Unlocking the full article...